Abstract: Isolated MHC-derived human peptides, particularly an isolated MHC-derived human peptide including a SDVGE-X-R (SEQ ID NO: 13) 7 amino acids motif that is selected from: NQEESVRFDSDVGEFR (Hpep 1-SEQ ID NO:1), NREEYARFDSDVGEFR (Hpep2-SEQ ID NO:2), NREEYVRFDSDVGEYR (Hpep4-SEQ ID NO:4) and any peptide with a length of 16 amino acids including the SDVGE-X-R (SEQ ID NO: 13) motif and having an amino acid sequence with at least 80, 85, 86, 87, 88, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity with SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 4. Also, the use of these peptides in methods for inducing an immune tolerance, for preventing or reducing transplant rejection or graft versus host disease (GVHD), and in methods for isolating and expanding a population of CD8+CD45RClow Tregs or for expanding a population of CD8+CD45RClow Tregs and stimulating its immunosuppressive activity.

Abstract: Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).

Abstract: Compounds of general formula: wherein R0A and R0B are independently selected from hydrogen and pharmaceutically acceptable cations; and RA and RB are identical and selected from amide, carbamate, sulphonamide, azido, cyano and halide. Also, a pharmaceutical composition including one of the compounds. The composition may also include another active ingredient, especially an antineoplastic agent. Further a compound or a composition for use as a medicament, especially a compound or a composition for use in the treatment of a proliferative disease such as for example cancer.

Abstract: For applications in the fields of organic electronics and photonics, disclosed are fluorescent charge-transfer compounds emitting in the visible spectral range from blue to red, including a triarylamine moiety, an electron-withdrawing group and at least two photopolymerizable groups. Also disclosed is a method for manufacturing a film-forming and photo-crosslinkable composition including at least one compound of the invention and its use as a precursor of a photocrosslinked emissive layer.

Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.

Abstract: The present invention relates to composite material comprising a matrix and a metallic layer located at at least one surface of said composite material, said matrix comprising at least one polymer and a first population of particles of at least one electronically conducting metal, said layer comprising a second population of particles of at least one electronically conducting metal, a method for preparing such composite material and applications thereof.

Abstract: Disclosed is a method for the culture of photosynthetic organisms selected from among microalgae, cyanobacteria and macroalgae using a continuous or discontinuous CO2 source.

Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Abstract: A method for controlling the operation of a robot within a system. The system includes the robot and sensors to analyze the concentric environment of the system. The sensors include a contact sensor, a proximity sensor and a vision and location sensor. For each of the axes of the robot, a maximum allowable force value is obtained. If the force on one of the axes of the robot is greater than the maximum value, the robot is stopped in its position. A concentric monitoring space or a security space is obtained as a function of the speed of the robot. The environment of the robot is monitored by the sensors. If the intrusion of an object is detected in the safe space of the robot, the maneuvering speed of the robot is gradually decreased to a safe speed. The process is repeated for the next axis of the robot.

Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

Abstract: The present invention relates to composite material comprising a matrix and a metallic layer located at at least one surface of said composite material, said matrix comprising at least one polymer and a first population of particles of at least one electronically conducting metal, said layer comprising a second population of particles of at least one electronically conducting metal, a method for preparing such composite material and applications thereof.

Abstract: The invention concerns a solution of tungstate ions W6+ (VI) comprising as solvent at least one optionally partly etherified polyalcohol, a preparation method and uses thereof. The invention further concerns a layer comprising at least one tungsten oxide WOz comprising one or more polyoxotungstate complexes, methods for preparing the same and uses thereof, and in particular a photovoltaic device comprising said layer of material.

Abstract: An optical fiber curvature sensor. Two networks (R1, R2) with periodic longitudinal modulation of the refractive index of the optical fiber core are inscribed in the fiber (F) one behind the other or one on top of the other. The networks are configured to respectively reflect wavelengths ?1 and ?2 such that ?1=?B+??B1 and ?2=?B+??B2, where ?B is the Bragg wavelength of the networks and where ?B1 and ?B2 are shifts sensitive to the temperature, to deformations and to the curvature of the optical fiber. The two networks are defined so that the quantities ??B1 and ??B2 have substantially identical sensitivity to temperature and to deformations and substantially opposite sensitivity to curvature.

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: Method and photo-electrochemical system using Cu(In,Ga)Se2 CIGS for reducing electrochemically CO2 into CO using as catalyst a metal complex with quaterpyridine ligand, the electrochemical cell comprising a cathode, an anode, a cathodic electrolyte comprising water as the solvent, and a power supply providing the energy necessary to trigger the electrochemical reactions.

Abstract: The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.

Abstract: The invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5 Kb by using an improved hybrid dual recombinant AAV vector system.

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: Anti-CD45RC antibodies, for use in the treatment of monogenic diseases caused by genes not associated with immune function but whose deficiency is associated with inflammation and/or immune reactions (such as genes deficient in Duchenne muscular dystrophy (DMD), cystic fibrosis, lysosomal diseases and al-anti-trypsin deficiency); or caused by genes involved in the immune system and whose deficiency generates inflammation and/or autoimmune reactions (such as genes deficient in T-cell primary immunodeficiencies such as IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome), APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy), B cell primary immunodeficiencies, Muckle-Wells syndrome, mixed autoinflammatory and autoimmune syndrome, NLRP12-associated hereditary periodic fever syndrome, and tumor necrosis factor receptor 1 associated periodic syndrome).

Abstract: A population of highly suppressive human CD8+CD45RClow/? Tregs is characterized by expressing Foxp3 and producing IFN?, IL-10, IL-34 and TGF? to mediate their suppressive activity. Accordingly, methods capable of increasing expansion and immunosuppressive capacity of such a population of CD8+CD45RClow/? Tregs are highly desirable for therapeutic purposes. Rapamycin has been shown to increase the expansion and immunosuppressive capacities of the population of CD8+CD45RClow/? Tregs. Accordingly, the method of increasing expansion and immunosuppressive capacity of a population of CD8+CD45RClow/? Tregs includes culturing the population of CD8+CD45RClow/? Tregs in presence of a rapamycin compound.